103 related articles for article (PubMed ID: 26146810)
1. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
Hahn M; Böttcher S; Dietrich S; Hegenbart U; Rieger M; Stadtherr P; Bondong A; Schulz R; Ritgen M; Schmitt T; Tran TH; Görner M; Herth I; Luft T; Schönland S; Witzens-Harig M; Zenz T; Kneba M; Ho AD; Dreger P
Bone Marrow Transplant; 2015 Oct; 50(10):1279-85. PubMed ID: 26146810
[TBL] [Abstract][Full Text] [Related]
2. Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients.
Kernan NA; Klein E; Mauguen A; Torok-Castanza J; Prockop SE; Scaradavou A; Curran K; Spitzer B; Cancio M; Ruggiero J; Allen J; Harris A; Oved J; O'Reilly RJ; Boelens JJ
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38643958
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.
Pasca S; Guo MZ; Wang S; Stokvis K; Shedeck A; Pallavajjala A; Shams C; Pallavajjala R; DeZern AE; Varadhan R; Gocke CD; Jones RJ; Gondek LP
Blood Adv; 2023 Aug; 7(16):4660-4670. PubMed ID: 37276081
[TBL] [Abstract][Full Text] [Related]
4. Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
Wienecke CP; Heida B; Venturini L; Gabdoulline R; Krüger K; Teich K; Büttner K; Wichmann M; Puppe W; Neziri B; Reuter M; Dammann E; Stadler M; Ganser A; Hambach L; Thol FR; Heuser M
Blood; 2024 Apr; ():. PubMed ID: 38669617
[TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.
Mussetti A; Rius-Sansalvador B; Moreno V; Peczynski C; Polge E; Galimard JE; Kröger N; Blaise D; Peffault de Latour R; Kulagin A; Mousavi A; Stelljes M; Hamladji RM; Middeke JM; Salmenniemi U; Sengeloev H; Forcade E; Platzbecker U; Reményi P; Angelucci E; Chevallier P; Yakoub-Agha I; Craddock C; Ciceri F; Schroeder T; Aljurf M; Ch K; Moiseev I; Penack O; Schoemans H; Mohty M; Glass B; Sureda A; Basak G; Peric Z
Bone Marrow Transplant; 2024 Feb; 59(2):232-238. PubMed ID: 38007531
[TBL] [Abstract][Full Text] [Related]
6. The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation.
Shouval R; Fein JA
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):715-722. PubMed ID: 38066892
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
Fürstenau M; De Silva N; Eichhorst B; Hallek M
Hemasphere; 2019 Oct; 3(5):e287. PubMed ID: 31942542
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
9. New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.
McClanahan F; Gribben J
Clin Adv Hematol Oncol; 2015 Sep; 13(9):586-94. PubMed ID: 26452190
[TBL] [Abstract][Full Text] [Related]
10. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
[TBL] [Abstract][Full Text] [Related]
11. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
12. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.
Pozzo F; Bittolo T; Arruga F; Bulian P; Macor P; Tissino E; Gizdic B; Rossi FM; Bomben R; Zucchetto A; Benedetti D; Degan M; D'Arena G; Chiarenza A; Zaja F; Pozzato G; Rossi D; Gaidano G; Del Poeta G; Deaglio S; Gattei V; Dal Bo M
Leukemia; 2016 Jan; 30(1):182-9. PubMed ID: 26165233
[TBL] [Abstract][Full Text] [Related]
13. The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review.
Puckrin R; Shafey M; Storek J
Front Oncol; 2022; 12():1105779. PubMed ID: 36741737
[TBL] [Abstract][Full Text] [Related]
14. Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.
Schwarzbich MA; Dai H; Kordelas L; Beelen DW; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216457
[TBL] [Abstract][Full Text] [Related]
15. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.
Dreger P; Dietrich S; Schubert ML; Selberg L; Bondong A; Wegner M; Stadtherr P; Kimmich C; Kosely F; Schmitt A; Pavel P; Liebers N; Luft T; Hegenbart U; Radujkovic A; Ho AD; Müller-Tidow C; Schmitt M
Blood Adv; 2020 Dec; 4(24):6157-6168. PubMed ID: 33351108
[TBL] [Abstract][Full Text] [Related]
16. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
[TBL] [Abstract][Full Text] [Related]
17. The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.
Selberg L; Stadtherr P; Dietrich S; Tran TH; Luft T; Hegenbart U; Bondong A; Meissner J; Liebers N; Schmitt M; Ho AD; Müller-Tidow C; Dreger P
Bone Marrow Transplant; 2021 Jan; 56(1):30-37. PubMed ID: 32555407
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.
Tournilhac O; Le Garff-Tavernier M; Nguyen Quoc S; Forcade E; Chevallier P; Legrand-Izadifar F; Laurent Damaj G; Michonneau D; Tomowiak C; Borel C; Orvain C; Turlure P; Redjou R; Guillerm G; Vincent L; Simand C; Lemal R; Quiney C; Combes P; Pereira B; Calvet L; Cabrespine A; Bay JO; Leblond V; Dhédin N; Organization Filo FIL; De Moelle Et de Thérapie Cellulaire Sfgm-Tc SFG
Haematologica; 2021 Jul; 106(7):1867-1875. PubMed ID: 32527951
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.
Michallet M; Dreger P; Sobh M; Koster L; Hoek J; Boumendil A; Scheid C; Fox CP; Wulf G; Krüger W; van Gelder M; Corradini P; Russo D; Passweg J; Schoemans H; Bethge W; Schaap N; Cornelissen J; Browne P; Durakovic N; Muller L; Montoto S; Kroger N; Schetelig J;
Bone Marrow Transplant; 2020 May; 55(5):884-890. PubMed ID: 31700137
[TBL] [Abstract][Full Text] [Related]
20. Methods and role of minimal residual disease after stem cell transplantation.
Ladetto M; Böttcher S; Kröger N; Pulsipher MA; Bader P
Bone Marrow Transplant; 2019 May; 54(5):681-690. PubMed ID: 30116018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
